Articles with public access mandates - Diego CadavidLearn more
Not available anywhere: 3
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy
P Vermersch, L Kappos, R Gold, JF Foley, T Olsson, D Cadavid, C Bozic, ...
Neurology 76 (20), 1697-1704, 2011
Mandates: Swiss National Science Foundation, US National Institutes of Health, Swedish …
Spirochetal infections
D Cadavid
Handbook of clinical neurology 96, 179-219, 2010
Mandates: US National Institutes of Health
Quantitative muscle analysis in facioscapulohumeral muscular dystrophy using whole‐body fat‐referenced MRI: Protocol development, multicenter feasibility, and repeatability
P Widholm, A Ahlgren, M Karlsson, T Romu, R Tawil, KR Wagner, ...
Muscle & nerve 66 (2), 183-192, 2022
Mandates: US National Institutes of Health, Netherlands Organisation for Scientific …
Available somewhere: 26
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open …
R Kapoor, PR Ho, N Campbell, I Chang, A Deykin, F Forrestal, N Lucas, ...
The Lancet Neurology 17 (5), 405-415, 2018
Mandates: US National Institutes of Health, National Institute for Health Research, UK
Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial
D Cadavid, L Balcer, S Galetta, O Aktas, T Ziemssen, L Vanopdenbosch, ...
The Lancet Neurology 16 (3), 189-199, 2017
Mandates: Multiple Sclerosis Society, UK
Clinically meaningful performance benchmarks in MS: timed 25-foot walk and the real world
MD Goldman, RW Motl, J Scagnelli, JH Pula, JJ Sosnoff, D Cadavid
Neurology 81 (21), 1856-1863, 2013
Mandates: US National Institutes of Health
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial
D Cadavid, M Mellion, R Hupperts, KR Edwards, PA Calabresi, J Drulović, ...
The Lancet Neurology 18 (9), 845-856, 2019
Mandates: Ministry of Education, Science and Technological Development of the Republic …
Acute optic neuritis: unmet clinical needs and model for new therapies
SL Galetta, P Villoslada, N Levin, K Shindler, H Ishikawa, E Parr, ...
Neuroimmunology & Neuroinflammation 2 (4), e135, 2015
Mandates: US National Institutes of Health, Government of Spain
Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS
SE Bushnell, Z Zhao, CC Stebbins, D Cadavid, AM Buko, ET Whalley, ...
Neurology 79 (6), 531-537, 2012
Mandates: US National Institutes of Health
Optimal intereye difference thresholds in retinal nerve fiber layer thickness for predicting a unilateral optic nerve lesion in multiple sclerosis
RC Nolan, SL Galetta, TC Frohman, EM Frohman, PA Calabresi, ...
Journal of Neuro-Ophthalmology 38 (4), 451-458, 2018
Mandates: US National Institutes of Health
Antibiotics for the neurological complications of Lyme disease
D Cadavid, PG Auwaerter, J Rumbaugh, H Gelderblom
Cochrane Database of Systematic Reviews, 2016
Mandates: National Institute for Health Research, UK
Antibodies to endothelial cell growth factor and obliterative microvascular lesions in the synovium of patients with antibiotic‐refractory Lyme arthritis
D Londoño, D Cadavid, EE Drouin, K Strle, G McHugh, JM Aversa, ...
Arthritis & rheumatology 66 (8), 2124-2133, 2014
Mandates: US National Institutes of Health
Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis
F Sellebjerg, D Cadavid, D Steiner, LM Villar, R Reynolds, D Mikol
Therapeutic Advances in Neurological Disorders 9 (1), 31-43, 2016
Mandates: Parkinson's UK
Identification and validation of clinically meaningful benchmarks in the 12-item Multiple Sclerosis Walking Scale
MD Goldman, MD Ward, RW Motl, DE Jones, JH Pula, D Cadavid
Multiple Sclerosis Journal 23 (10), 1405-1414, 2017
Mandates: US National Institutes of Health
IL-10 Prevents apoptosis of brain endothelium during bacteremia
D Londoño, J Carvajal, K Strle, KS Kim, D Cadavid
The Journal of Immunology 186 (12), 7176-7186, 2011
Mandates: US National Institutes of Health
IL-10 helps control pathogen load during high-level bacteremia
D Londono, A Marques, RL Hornung, D Cadavid
The Journal of Immunology 181 (3), 2076-2083, 2008
Mandates: US National Institutes of Health
Role of interleukin 10 during persistent infection with the relapsing fever Spirochete Borrelia turicatae
H Gelderblom, J Schmidt, D Londono, Y Bai, J Quandt, R Hornung, ...
The American journal of pathology 170 (1), 251-262, 2007
Mandates: German Research Foundation
Phase 1 clinical trial of losmapimod in facioscapulohumeral dystrophy: Safety, tolerability, pharmacokinetics, and target engagement
ML Mellion, L Ronco, CL Berends, L Pagan, S Brooks, MJ van Esdonk, ...
British Journal of Clinical Pharmacology 87 (12), 4658-4669, 2021
Mandates: Netherlands Organisation for Scientific Research, European Commission …
Bacterial lipoproteins can disseminate from the periphery to inflame the brain
D Londono, D Cadavid
The American journal of pathology 176 (6), 2848-2857, 2010
Mandates: US National Institutes of Health
Structure-Function Investigation of Vsp Serotypes of the Spirochete Borrelia hermsii
R Mehra, D Londono, M Sondey, C Lawson, D Cadavid
PLoS One 4 (10), e7597, 2009
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program